Last A$0.27 AUD
Change Today +0.01 / 3.85%
Volume 87.8K
As of 10:34 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

idt australia ltd (IDT) Snapshot

Open
A$0.26
Previous Close
A$0.26
Day High
A$0.28
Day Low
A$0.26
52 Week High
11/7/13 - A$0.52
52 Week Low
06/24/14 - A$0.19
Market Cap
20.9M
Average Volume 10 Days
3.8K
EPS TTM
A$-0.13
Shares Outstanding
77.4M
EX-Date
10/5/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IDT AUSTRALIA LTD (IDT)

Related News

No related news articles were found.

idt australia ltd (IDT) Related Businessweek News

No Related Businessweek News Found

idt australia ltd (IDT) Details

IDT Australia Limited, a pharmaceutical contract manufacturing company, provides products, research and development, and other technical services for the pharmaceutical and allied industries primarily in Australia. It is involved in the development, scale-up, and production of high potency active pharmaceutical ingredients, cytotoxic active pharmaceutical ingredients, hormones, and toxic reagents. The company’s product portfolio comprises anti-cancer drugs, anti-psychotics, antibiotics, narcotics, and anti-inflammatory drugs. It also offers a range of specialist formulation development manufacturing, packaging, and dispensing services for new products and clinical trial supplies; manufactures active and placebo clinical trial supplies in various dosage forms, such as tablets, capsules, suspensions, liquids, and ointments; and consultancy services in the areas of blinding, randomization, code breaks, labeling, packaging, storage and distribution of drugs, and retrieval and disposal of supplies. In addition, the company provides support services for new drug development and scale-up projects through its laboratory facilities. Further, it offers a range of services comprising feasibility assessments; cost estimates; study conduct; project planning and management; protocol and informed consent development; preparation, submission, and tracking of ethics applications; CTN/CTX preparation and submission; case report form design; investigator selection; site selection; healthy subject recruiting; patient recruiting; adverse event recording and reporting; data entry and quality control; processing and sample storage; and commercial sponsorship for the design, implementation, and management of clinical studies. The company is based in Boronia, Australia.

idt australia ltd (IDT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$63.8K
Founder, Director, Member of Nomination Commi...
Total Annual Compensation: A$113.7K
Vice President of Legal & Corporate Developme...
Total Annual Compensation: A$32.5K
Vice President of Clinical Services and Gener...
Total Annual Compensation: A$180.6K
Compensation as of Fiscal Year 2013.

idt australia ltd (IDT) Key Developments

IDT Australia Ltd Announces Executive Changes

IDT Australia Ltd. announced the appointment of Ms. Joanna Johnson to the role of Chief Financial Officer and Company Secretary, effective March 18, 2014. Joanna is a Chartered Accountant and has over 18 years' experience in financial roles within the pharmaceutical industry. Joanna joins IDT from Generic Health, where in her role as CFO the company grew substantially and ultimately became majority owned by the Indian company Lupin. In addition to Ms. Johnson's appointment, IDT appoints Dr. David Sparling as joint Company Secretary. Ms. Johnson succeeds Mr. Roman Najdecki as Chief Financial Officer and Company Secretary of IDT Australia. Mr. Najdecki is retiring after a long and successful career leading the finance function at many Australian biotechnology and pharmaceutical companies.

IDT Australia Limited Announces Earnings Results for the Half Year Ended December 31, 2013

IDT Australia Limited announced earnings results for the half year ended December 31, 2013. For the year, the company reported revenue of AUD 6,539,000 against AUD 5,090,000 a year ago. Loss from period before income tax benefit was AUD 2,259,000 against AUD 1,683,000 a year ago. Loss attributable to members of the company was AUD 2,176,000 or 3.1 cents per basic and diluted share against AUD 967,000 or 2.2 cents basic and diluted share a year ago. Net cash used in operating activities was AUD 58,000 against AUD 144,000 a year ago. Payments for property, plant & equipment were AUD 65,000 against AUD 230,000 a year ago.

IDT Australia Limited Announces Resignation of Roger Aston as Director

Dr Roger Aston has advised the board that following his appointment as Executive Chairman of Pharmaust Limited he will no longer be able to devote the necessary time and resource to add value as a director of IDT Australia Limited and as such has tendered his resignation effective immediately.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDT:AU A$0.27 AUD +0.01

IDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDT.
View Industry Companies
 

Industry Analysis

IDT

Industry Average

Valuation IDT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDT AUSTRALIA LTD, please visit www.idtaus.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.